APP and colorectal carcinoma: CRC may inhibit the activity of β-secretase to reduce the levels of Aβ [79,86] and the APP metabolic pathway to lower Aβ levels [84], and also regulate Aβ production by inhibiting GSK-3β-mediated presenilin-1 activation [87].